Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Voruciclib as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory B-Cell Malignancies and Relapsed/Refractory Acute Myeloid Leukemia

Next Previous
Trial Profile

A Phase 1 Study of Voruciclib as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory B-Cell Malignancies and Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Venetoclax (Primary) ; Voruciclib (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • Focus Adverse reactions
  • Sponsors MEI Pharma

    • Most Recent Events

    • 07 Feb 2019 According to a MEI Pharma media release, initial clinical results from this ongoing study of voruciclib, including single agent dose ranging data and results from the combination with venetoclax in patients with B-cell malignancies and relapsed and refractory acute myeloid leukemia is expected by end of 2019.
    • 11 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 15 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top